Confidential and Proprietary

Moving Precision Health from Rhetoric to Reality

August, 2019

Safe Harbor statement

This presentation contains forward-looking statements. These statements relate to future events or SomaLogic’s future financial performance. Any statements that are not statements of historical fact should be considered forward-looking statements. There are a number of important factors that could cause SomaLogic’s actual results to differ materially from the assumptions made in the model, including changes in market conditions, inability to penetrate markets, changes in technology, and changes in pricing models. SomaLogic disclaims any obligation to update any forward-looking statement.

2

Experienced leadership

Roy SmytheChief Executive Officer

Melody HarrisPresident

Matt NorkunasChief Financial Officer

Nebojsa JanjicChief Science Officer

Stephen WilliamsChief Medical Officer

Alan WilliamsChief Development and Operations

Fintan SteeleChief Communications and Culture

About SomaLogic

▶ Founded in 2000 by Larry Gold, PhD

▶ Located in Boulder, CO

▶ 200 employees

▶ $600M invested to date ($365M in equity)

Basic facts

Larry Gold, Founder & ChairmanSynergen, NeXagen, NeXstar

Charles M. LillisFormer Chairman and CEO, Media One Group, Inc.; Co-founder and Managing Partner, LoneTree Capital

Jessica MathewsFormer President, Carnegie Endowment forInternational Peace

Alister (Al) W. ReynoldsFormer SVP of US Operations, Quest Diagnostics

Terry L. RandallPresident-CEO, Heritage Capital, LLC

Takayuki ShiratsuchiOperating Officer, General Manager of Basic Research, Otsuka Pharmaceuticals

Roy SmytheCEO, SomaLogic; former Chief Medical Officer for Strategy and Partnerships, Royal Philips

Jun WangFounder and CEO of iCarbonX,former CEO and Chairman of BGI

Board of Directors Advisors

Sir Marc FeldmannEmeritus Professor, University of Oxford, UK

Peter GanzProfessor, UCSF School of Medicine

David LawrenceFormer Chairman & CEO, Kaiser Permanente

Craig MundiePresident, Mundie & Associates; Former Chief Research and Strategy Officer, Microsoft

Russell RayFormer Vice Chair and Managing Director of Healthcare Investment Banking, Stifel

Elio RiboliDirector, School of Public Health, Imperial College, London

John Stuelpnagel Executive Chairman, Ariosa Diagnostics; Chairman, 10x Genomics; Founder and former CEO and COO, Illumina

3

Nature can refuse to speak, but she cannot give a wrong answer.

Charles Brenton Huggins, MDNobel Prize for Medicine or Physiology, 1966

4

The well-known challenge of precision health

THE TOP 5%

WALKING WOUNDED

UNDER THE RADAR

ON THE LEDGE

“HEALTHY”

PREDISPOSED

5

Moving fromrhetoric to reality

▶ To understand human biology in context, you must translate the “language” of proteins in real-time.

▶ After 20 years of effort, SomaLogicleads the world in translating proteins into impactful health information.

▶ We are creating a truly transformational protein-based precision health information company.

6

Commercial launch of SomaSignal™ tests

100

5,000-plex launched under CLIA

Creating a transformational protein-based precision health information company

7

20062000-2005 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

Som

aS

can®

ple

x si

ze

Dilu

tive

fun

din

g ($

M)

4005000

1000

SomaLogic founded by Larry Gold

First version of SomaScan®

Assay deployed

First commercial sale of SomaScan® Assay

First collaborative deal with Novartis

Pivot from life sci tools business to clinical proteomics / health information

Roy Smythe (CEO) and Melody Harris (President) join SomaLogic

CLIA / CAP accreditation

Expansion of Novartis agreement

First scientific publication of SomaScan® Assay

yr.

RED – SomaScan plex sizeBLUE – Dilutive funding

Publication in JAMA presages first SomaSignal™ test

SomaLogic Differentiation in the Market

8

What genes measure, what proteins measureWhile beneficial, genomic testing is neither comprehensive nor contextual

9

Precision health relies on the acquisition and interpretation of “real-time” biologic data

10

mRNA

Molecule that carries “directions” for

protein synthesis

Proteins

Primary functional and structural molecules for all

biological processes

DNA

Hereditary material that encodes biological

molecules

One-and-done Repeat regularly

From static to dynamic measurements

New applications of genomics can expand progress, but proteomics offers near limitless growth

11

Protein measurement

Covers all of human biology in real time - all diseases, conditions and

normal processes

(SomaLogic)

Cell-free DNA

Limited to diseases and conditions that shed

marker DNA

(E.g., Guardant)

T-cell recognition

Limited to diseases and conditions that effectively

activate T-cells

(E.g., Adaptive Biotechnologies)

Several direct competitors No direct competitors

The SomaScan® Assay uniquely meets the requirements for proteomics-based precision health

12

Breadth (number)

Depth (low conc)

Speed

Cost

Scalability

Reproducibility

Sample needed

Antibodies Mass spec SomaScan®

- Yes

- No

- Partial

▶ Proprietary technology / science

▶ ~5,000 proteins in each sample(equivalent to 5,000 ELISAs)

▶ Can detect low concentration proteins

▶ Many assays can run simultaneously(faster, less expensive)

▶ Scalable and reproducible

▶ Runs in CLIA-certified laboratory

▶ Small biological sample volume

How we measure proteins - SOMAmer® reagents and the SomaScan® AssayTurning a protein measurement challenge into a DNA measurement solution

Platelet-derived growth factor and specific SOMAmer reagentCustom array measuring ~5K SOMAmer reagents

Slow Off-rate Modified Aptamers (SOMAmers): Next generation protein

binders

Synthetic single-stranded DNA structures, with ”protein-like” modifications

The SomaScan® Assay combines 1,000s of different SOMAmer® reagents to measure

1,000s of different proteins in a small volume of biological sample

Unmatched specificity, sensitivity, dynamic range, reproducibility, scalability and speed

13

The SomaScan® Assay is scalable, and has created the world’s largest clinical proteomics database

* At time of acquisition

GuardantHealth

SomaLogicFoundationMedicine

AdaptiveBiotechnologies

80k 100k

180k*

300k

~300k samples to date on the SomaScan Assay

100k

300k

200k

# sa

mpl

es

14

>200

>600

~300ksamples

processed to date using the

SomaScan Assay

peer-reviewedpublications on the technology and its

applications

patents issued and pending worldwide

World-class strategic partnerships

> 100 academic collaborations

▶ Massachusetts General Hospital▶ Dana Farber Cancer Institute▶ Beth Israel Deaconess Medical Center▶ Johns Hopkins University▶ Yale University▶ University of Pennsylvania▶ University of California, San Francisco▶ Erasmus Medical Center▶ Oxford University▶ University of Cambridge

The SomaScan® Assay has been heavily vetted by collaborators, publications and patents

15

Our product development process - from proteins to health information

1

2

3

4

5

6

7

8

9

10

11

12

19

13

14

15

16

17

18

20

21

~300ksamples

processed to date using the

SomaScan Assay SomaSignal™ tests

16

SomaSignal™ tests undergo rigorous developmentExample: Cardiovascular Secondary Event Prediction

▶ Predefined minimum performance criteria• A positive Net Reclassification Index (NRI) compared with

best combination of risk factors▶ Model output:

• 4 year relative probability of any major CV event or death

▶ Actual performance• Model has 27 proteins and no demographic factors• The NRI vs. risk factors was highly positive (+0.53 in

validation)• The AUC (0.74 in validation) was superior to risk factors

(0.53)

17

HUNT 3 (Norway) N = 606

ARIC (USA) N = 784

Training Set (no known disease)

Independent Replication Set

Machine learning approaches are employed, and models vary between tens and hundreds of informative proteins

SomaSignal™ tests versus existing diagnostic alternatives, and polygenic risk assessment

CV Primary vs. outcomes

CV Secondary vs. outcomes

Liver fat vs. ultrasound

% Body Fat vs. DEXA

Lean body mass vs. DEXA

Cardio-respiratory fitness vs. VO2 max

Alcohol impact vs. self report

Visceral fat vs. DEXA

Glucose tolerance vs. OGTT

Performance (r2 [0-1.0] or AUC [0.5-1.0])

Best possible performance

ACC risk

Best factors

Impedance

Best factors

Impedance

Best factors

Adiponectin

Liver enzyme

Best factors

18

We leverage a network effect to develop new SomaSignal tests, and make them increasingly informative

BiobanksPharmaAcademicsClinical Partners

Data repositoryIT / analytics

101010001101101010001011100100100001000011111110

Clinical andconsumer

1

2

3

4

5

6

7

8

9

10

11

12

19

13

14

15

16

17

18

20

21

19

SomaSignal™ tests

By 2024, there will be more than 1 million human specimens in the SomaLogicclinical proteomics database, and by 2028 - more than 4 million

One tube of blood – unlimited tests, unlimited timesThe SomaScan® Platform scales like a digital platform

Value = X (one tube) Value + Xn (many tests) Value + Xn(X) (many times)

Sept Oct Nov

Dec Jan Feb

How am I doing now?Making progress?

How is my patient doing now?Making progress?

SomaSignal™ tests

20

There are more than 100 tests in the SomaSignal™ pipeline – and all can be run on any one sample

21

Medical

Primary CV riskSecondary CV riskLiver fatGlucose tolerance

Health/Wellness

Resting metabolic rateMacronutrient statusAerobic Fitness/VO2 MaxAlcohol consumptionVisceral Body FatLean Body MassPercent Body Fat

Medical

NASHNASH subtypesCancer susceptibilityChronic Kidney Disease prognosisCongestive Heart Failure prognosisCongestive Heart Failure type

Functionally relevant CHDStatin adherencePredict Renal Failure w/ CVDeGFR (kidney function)Predict Type II Diabetes onsetPredict Diabetic Retinopathy

Health/Wellness

HealthspanSleep qualityAlzheimers/Dementia riskCognitive functionBiologic/functional ageTraining statusSocial deprivationSmoking status

Physical activityBody weightBone Mineral MassLifespanEnergy balanceVitamin C levelInsulin sensitivity

Medical

Cancer risk (top 15)Cancer risk (other subtypes)Acute Kidney InjuryCKD w/diabetesCOPD risk/risk of progressionAnticoagulant adherenceCHF hospitalization riskCHF therapy sensitivity

CV disease w/ diabetesCoronary artery calcium surrogatePrimary CV risk (multiple subtypes)eGFR (kidney function) trajectoryFunctional status/ability w/agingPulmonary functionSleep apnea riskPeripheral vascular function

Health/Wellness

Circadian cycleDaily physical activityMetabolic flexibilityReproductive healthCognitive trajectoryDepression/mood w/agingFrailtyGenderGrip strength w/agingMaximum strength

Mental stressInflammatory loadMicrobiome diversityDiet change/hypertension correlationTraining program recommendationEnduranceFood allergy riskJoint healthMacronutrient status/weight loss correlation

Fall 2019 Release 2019 - 2020 2020+

SomaLogic Business Plan and Direction

22

Go-To-Market Plan:Support for precision health across channels

23

Self Pay and Concierge

Medical

Retail/Direct to

Consumer

Health assessments and care delivery

SomaScan® Assay protein quantification and SomaSignal™ tests for clinical drug trials

Data collaboration for SomaLogic proteomics database development

Patient / Individual

Risk-bearing Medical (health

systems, etc.)

2019 2020 2021Pharma,

Biotech and Academic

2017

The go-to-market sequence rationale is sound

24

Retail/Direct to

Consumer

Pharma, Biotech and Academic

Self-Pay and Concierge

Medical

Risk-bearing Medical (health

systems, etc.)

Development of SomaLogic proteomics

database

Source of recurring baseline development

revenue

Develop health system utility proof

Self-pay experience in hand

Larger platform of medical tests for pop health management

Motivated providers and patients

Dispensable income

KOL development for risk bearing medical

and DTC

Medical acceptance and advocacy

Consumer launch

Develop DTC commercial

competencies

Lowered assay for DTC price points

Urine as a matrix

25

Retail/Direct to

Consumer

Pharma, Biotech and Academic

Self-Pay and Concierge

Medical

Risk-bearing Medical (Health

Systems, etc.)

Compete in global market

Clinical trial support –patient selection

Clinical trial support –drug discovery

Disease understanding

Enhanced experience

Compete in innovative market

Efficient referrals

MD productivity

Lower cost diagnostics

Cost-effective baseline

Enhanced experience

Population mgmt

Decrease hospitalizations

MD productivity

Lower cost diagnostics

Cost-effective baseline

Financial / family planning

Disease self-mgmt

Healthier lifestyle opportunity

Convenience

The value proposition for each market is substantial

The US market opportunity alone is $50B

▶ Two-year continuous engagement with external firm for:• Market research and interviews for product concept and development• Validation of product concept, go-to-market plan and value proposition• Sizing and characterization of markets

• Sensitivity analyses for pricing and revenues

26

Retail/Direct to

Consumer

Pharma, Biotech and Academic

Self-Pay and Concierge

Medical

Risk-bearing Medical (health

systems, etc.)

$900M-$2B $3.7B $13.7B $30.4BTAM (US):

Data aggregation and advanced computing will create significant revenue opportunities4M human specimens in the SomaLogic database by 2028

▶ Consumer Decision Support Engines• ”With your proteomic profile, you should do X to improve sleep, fitness,

etc.”

▶ Clinical Decision Support Engines• “With this proteomic profile, this patient will benefit from treatment X”

▶ “Predicting the Next Proteome”• Analytics allowing the use of intercurrent urine as matrix, or no biologic

specimen at all to register proteomic profile and prediction(s)

▶ The Liquid Physical Exam• Mapping of typical history, physical and conventional diagnostic test data

points to proteomic data, at times eliminating their need

▶ Monetization of Comprehensive Database Insights

27

▶ To understand human biology in context, you must translate the “language” of proteins in real-time, and ideally repeatedly over time.

▶ After 20 years of effort, SomaLogicleads the world in translating proteins into impactful health information, and the value of our information will compound greatly over time.

▶ We are creating a truly transformational protein-based precision health information company.

28